synthetic gastric pentadecapeptide

BPC-157

BPC-157 is a gastric pentadecapeptide studied in preclinical models of tissue integrity, angiogenesis, and NO signaling.

Also referred to as: Body Protection Compound 157, PL 14736, stable gastric pentadecapeptide BPC 157
Research use only. This page summarizes published scientific literature. It is not medical advice, not a recommendation, and not a claim that this compound treats, cures or prevents any condition. Nothing here is a suggestion to use it.

What BPC-157 is

BPC-157 is a 15-amino-acid peptide derived from a body-protection-compound sequence associated with gastric juice research. Most published work is preclinical, with animal models examining wound repair, tendon and ligament injury, gastrointestinal integrity, vascular responses, and nitric-oxide-system interactions. Human evidence is much thinner than internet discussion suggests.

Because the literature is dominated by rodent and other animal models, BPC-157 education needs careful framing. Research-grade BPC-157 is Research Use Only and is not an approved drug product. Reported ranges below reflect published animal-study exposure styles and should not be converted into human protocols.

Nearly all of the published work on BPC-157 is preclinical: animal models and cell studies. Human evidence is thinner than the volume of online discussion suggests.

How it works

BPC-157 is studied for interactions with cytoprotective pathways, angiogenesis-related signaling, nitric oxide balance, and tissue-response networks. Preclinical papers describe effects on vascular integrity, growth-factor expression, inflammatory responses, and gastrointestinal mucosal resilience. The exact receptor-level mechanism is not settled, and much of the evidence comes from model-specific injury systems. That uncertainty is why species, route, and endpoint matter so much in BPC-157 interpretation.

Who studies it, and why

BPC-157 is studied mainly by preclinical pharmacology groups, gastrointestinal researchers, sports-medicine reviewers, and analytical laboratories. Human clinical researchers generally treat the evidence base as preliminary and not interchangeable with approved peptide therapeutics.

What the research examines

wound healing modelstendon and ligament researchgastrointestinal integrityangiogenesis signalingnitric oxide pathways

These are areas of active investigation. Listing a topic here does not mean an effect is established, approved, or proven in humans.

How it appears in the literature

Amounts reported in published research, shown for reference. Not a protocol.

Research contextReported amountFrequencyRoute
Preclinical BPC-157 animal studies frequently report ng/kg to mcg/kg exposure bands0.01 mcg – 10 mcgvaries by animal modelintraperitoneal, oral, topical, or local in animal studies
Rodent injury and gastrointestinal models often cite 10 mcg/kg as an experimental exposure10 mcgmodel-dependentanimal-study routes vary
See the full BPC-157 dosage chart, reconstitution math and calculator →

Handling & storage

Lyophilized BPC-157 is commonly stored frozen or refrigerated, dry, and protected from light; reconstituted research solutions are usually refrigerated and handled aseptically.

Notes on combined research

BPC-157 is commonly paired in online discussion with TB-500, GHK-Cu, or recovery-focused compounds, but those combinations outrun the human evidence. Research protocols should isolate injury model, route, and endpoint before combining peptides, especially when the base evidence is preclinical.

BPC-157 questions

Published BPC-157 research is mostly animal work, often reported as ng/kg or mcg/kg. Those values are reference information and are not human dosing instructions.

Common research examples use 1-3 mL for 5-10 mg vials. Reconstitution volume changes concentration only.

Daily BPC-157 schedules in online charts are not the same as published study protocols. A literature-based answer must specify species, route, and model.

A responsible chart should separate animal-study mcg/kg values from vial concentration math and should avoid presenting either as a recommendation.

Preclinical studies often assess endpoints over days to weeks depending on the injury model. There is no universal timeline.

A clinically useful human half-life has not been established. Stability and exposure are discussed mostly in research-model terms.

It can be studied with other compounds, but stacking makes attribution difficult and is not supported as a human-use protocol.

Read the research yourself

Every link below was verified against the NCBI PubMed database. We do not cite what we cannot point you to.

Reference information only. The values below summarize amounts reported in published research literature and laboratory protocol discussions. They are not dosing recommendations, not medical advice, and not instructions for use in humans. All compounds referenced are for laboratory research use only and are not for human consumption.